Impact of infant pneumococcal conjugate vaccination on community acquired pneumonia hospitalization in all ages in the Netherlands

被引:20
作者
van Deursen, A. M. M. [1 ,2 ,3 ]
Schurink-van't Klooster, T. M. [4 ]
Man, W. H. [1 ,3 ]
van de Kassteele, J. [5 ]
van Gageldonk-Lafeber, A. B. [4 ]
Bruijning-Verhagen, P. C. J. L. [2 ,4 ]
de Melker, H. E. [4 ]
Sanders, E. A. M. [1 ,4 ]
Knol, M. J. [4 ]
机构
[1] Wilhelmina Childrens Hosp, Univ Med Ctr Utrecht, Dept Pediat Immunol & Infect Dis, Utrecht, Netherlands
[2] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands
[3] Spaarne Gasthuis Acad, Res Ctr, Hoofddorp, Netherlands
[4] Natl Inst Publ Hlth & Environm, Ctr Infect Dis Control, Dept Epidemiol & Surveillance, Bilthoven, Netherlands
[5] Natl Inst Publ Hlth & Environm, Dept Stat Informat & Math Modelling, Bilthoven, Netherlands
关键词
Pneumococcal conjugate vaccine; PCV7; PCV10; Pneumonia; Epidemiology; Hospitalization rates; SEROTYPE REPLACEMENT; CHILDREN YOUNGER; DISEASE; EPIDEMIOLOGY; ADMISSIONS; PREVENTION; MORTALITY; VACCINES; DECLINE; ENGLAND;
D O I
10.1016/j.vaccine.2017.10.090
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: The long-term impact of pneumococcal conjugate vaccines on pneumonia hospitalizations in all age-groups varies between countries. In the Netherlands, the 7-valent pneumococcal conjugate vaccine (PCV7) was implemented for newborns in 2006 and replaced by PCV10 in 2011. We assessed the impact of PCVs on community-acquired pneumonia (CAP) hospitalization rates in all age-groups. Methods: A time series analysis using Poisson regression was performed on 155,994 CAP hospitalizations. Hospitalization rates were calculated using the total number of hospitalizations as denominator. The time trend in the pre-PCV period (1999-2006) was extrapolated to predict the hospitalization rate in the post-PCV period (2006-2014) if PCV had not been implemented. Rate ratios over time were calculated by comparing observed and predicted time trends. Results: In children <5 years of age, the observed hospitalization rates during the post-PCV period were significantly lower than predicted if PCV had not been implemented (0-6 months: 0.62, 95% CI: 0.410.96; 6 months - 1 year: 0.67, 95% CI: 0.50-0.90; 2-4 years: 0.78, 95% CI: 0.61-0.97). In all other age groups, rate ratios declined over time but did not reach statistical significance. Conclusions: After introduction of PCV, CAP hospitalizations declined in young children but no clear impact of PCV on CAP hospitalizations was seen in other age-groups. (C) 2017 Elsevier Ltd. All rights reserved.
引用
收藏
页码:7107 / 7113
页数:7
相关论文
共 57 条
  • [1] Arguedas Adriano, 2011, Vaccine, V29 Suppl 3, pC26, DOI 10.1016/j.vaccine.2011.06.104
  • [2] A population-based study on the impact of hospitalization for pneumonia in different age groups
    Baldo, Vincenzo
    Cocchio, Silvia
    Baldovin, Tatjana
    Buja, Alessandra
    Furlan, Patrizia
    Bertoncello, Chiara
    Russo, Francesca
    Saia, Mario
    [J]. BMC INFECTIOUS DISEASES, 2014, 14
  • [3] Diagnostic Tests for Agents of Community-Acquired Pneumonia
    Bartlett, John G.
    [J]. CLINICAL INFECTIOUS DISEASES, 2011, 52 : S296 - S304
  • [4] All-Cause Pneumonia Hospitalizations in Children &lt;2 Years Old in Sweden, 1998 to 2012: Impact of Pneumococcal Conjugate Vaccine Introduction
    Berglund, Anders
    Ekelund, Mats
    Fletcher, Mark A.
    Nyman, Lars
    [J]. PLOS ONE, 2014, 9 (11):
  • [5] Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia
    Black, SB
    Shinefield, HR
    Ling, S
    Hansen, J
    Fireman, B
    Spring, D
    Noyes, J
    Lewis, E
    Ray, P
    Lee, J
    Hackell, J
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2002, 21 (09) : 810 - 815
  • [6] Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults
    Bonten, M. J. M.
    Huijts, S. M.
    Bolkenbaas, M.
    Webber, C.
    Patterson, S.
    Gault, S.
    van Werkhoven, C. H.
    van Deursen, A. M. M.
    Sanders, E. A. M.
    Verheij, T. J. M.
    Patton, M.
    McDonough, A.
    Moradoghli-Haftvani, A.
    Smith, H.
    Mellelieu, T.
    Pride, M. W.
    Crowther, G.
    Schmoele-Thoma, B.
    Scott, D. A.
    Jansen, K. U.
    Lobatto, R.
    Oosterman, B.
    Visser, N.
    Caspers, E.
    Smorenburg, A.
    Emini, E. A.
    Gruber, W. C.
    Grobbee, D. E.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (12) : 1114 - 1125
  • [7] Estimating the population-level impact of vaccines using synthetic controls
    Bruhn, Christian A. W.
    Hetterich, Stephen
    Schuck-Paim, Cynthia
    Kueruem, Esra
    Taylor, Robert J.
    Lustig, Roger
    Shapiro, Eugene D.
    Warren, Joshua L.
    Simonsen, Lone
    Weinberger, Daniel M.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2017, 114 (07) : 1524 - 1529
  • [8] Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial
    Cutts, FT
    Zaman, SMA
    Enwere, G
    Jaffar, S
    Levine, OS
    Okoko, JB
    Oluwalana, C
    Vaughan, A
    Obaro, SK
    Leach, A
    McAdam, KP
    Biney, E
    Saaka, M
    Onwuchekwa, U
    Yallop, F
    Pierce, NF
    Greenwood, BM
    Adegbola, RA
    [J]. LANCET, 2005, 365 (9465) : 1139 - 1146
  • [9] de Greeff S C, 2007, Ned Tijdschr Geneeskd, V151, P1454
  • [10] Antimicrobial Drug Use and Resistance in Europe
    de Sande-Bruinsma, Nienke Van
    Grundmann, Hajo
    Verloo, Didier
    Tiemersma, Edine
    Monen, Jos
    Goossens, Herman
    Ferech, Matus
    [J]. EMERGING INFECTIOUS DISEASES, 2008, 14 (11) : 1722 - 1730